COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111
Randomized, Placebo-Controlled, Phase 2 Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)
Sponsor: Veru Inc.
This PHASE2 trial investigates Respiratory Distress Syndrome, Adult and is currently completed. Veru Inc. leads this study, which shows 15 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Completed PHASE2
-
Dec 2021 — Sep 2022 [monthly]
Completed PHASE2
▶ Show 10 earlier versions
-
Nov 2021 — Dec 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE2
-
Apr 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
Mar 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE2
-
Aug 2020 — Oct 2020 [monthly]
Recruiting PHASE2
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE2
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Veru Inc.
For direct contact, visit the study record on ClinicalTrials.gov .